β-hCG Vaccine
Alternative Name: β-human chorionic gonadotropin
Description: β-human chorionic gonadotropin (β-hCG) is a candidate immunogens to develop immunocontraceptive vaccine for human application.
Product Details
User: Female
Hormonal: No
Duration Type: Long-acting
Multipurpose Preventive Technology (MPT): No
Status Details
Developer: Talwar Research Foundation, Indian Council for Medical Research
Project Phase: Pre-Clinical and Clinical Development
Development Stage: Phase II
Active Development: Unknown
Status Details: - Phase II trials were completed in 1994. After a phase of inactivity, work began on a recombinant vaccine, which could be amenable to industrial
production. Preclinical work on the reconfigured vaccine has been undertaken and there are plans to restart clinical trials.
- Phase II trials were completed in 1994. After a phase of inactivity, work began on a recombinant vaccine, which could be amenable to industrial production. Preclinical work on the reconfigured vaccine has been undertaken and there are plans to restart clinical trials.
Additional Information
References: Talwar GP, et al. (1994) A vaccine that prevents pregnancy in women. Proc Natl Acad Sci. 30;91(18):8532-6.
Talwar GP, et al. (2015) Advances in development of a contraceptive vaccine against human chorionic gonadotropin. Expert Opinion on Biological Therapy. 15:8.
Talwar GP, et al. (1994) A vaccine that prevents pregnancy in women. Proc Natl Acad Sci. 30;91(18):8532-6.
Talwar GP, et al. (2015) Advances in development of a contraceptive vaccine against human chorionic gonadotropin. Expert Opinion on Biological Therapy. 15:8.
Footnotes: - See also entry on CTP of β-hCG vaccine.
- See also entry on CTP of β-hCG vaccine.